Status:
RECRUITING
Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular Drainage
Lead Sponsor:
Aaron Cook
Collaborating Sponsors:
Cumberland Pharmaceuticals
Conditions:
Subarachnoid Hemorrhage, Aneurysmal
Eligibility:
All Genders
18-85 years
Phase:
PHASE4
Brief Summary
The proposed study aims to evaluate the CNS penetration of telavancin in a critically ill population using cerebrospinal fluid (CSF) drawn from external ventricular drains (EVDs). Patients with EVDs w...
Detailed Description
Telavancin exhibits potent and durable activity against target pathogens for bacterial meningitis and ventriculitis. There is a potential role for telavancin in treating Gram positive CNS pathogens, p...
Eligibility Criteria
Inclusion
- Adult aged 18-85 years
- Actively draining ventriculostomy
Exclusion
- history of hypersensitivity to telavancin or similar agents
- reduced renal function (estimated creatinine clearance \< 50/ml) at the time of consent
- severe anemia (hemoglobin \< 7gm/dl)
- vulnerable population (pregnant, prisoner)
- concomitant antimicrobial therapy
Key Trial Info
Start Date :
July 2 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06119061
Start Date
July 2 2024
End Date
December 1 2026
Last Update
December 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Kentucky
Lexington, Kentucky, United States, 40536